Fundraising Fox
New York · Pre-Seed–Series B · 21 people tracked
Also known as MEDICAL EXCELLENCE CAPITAL, LLC
Find your way into Medical Excellence Capital
Each arrow is one introduction. Sign up to fill in the first one.
Ask Kevin Emesiani to introduce you to Kim Kamdar
You →Kevin · together at Medical Excellence Capital →Kim
Ask Jamie Chen to introduce you to Eric Heil
You →Jamie · together at Easton Associates →Eric
Ask Sam Okafor to introduce you to John Hornbostel
You →Sam · together at Medical Excellence Capital →John
- Max Colbert328 people can intro you
- Victoria Lewis205 people can intro you
- Brian Halak190 people can intro you
Sign up to find every way you can get introduced to Medical Excellence Capital
- Your email: who you already know at Medical Excellence Capital, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Medical Excellence Capital team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
MEC is a purpose-built venture firm investing in precision health and life sciences innovation. It backs company creation, seed, Series A, and Series B opportunities where technology and novel approaches — often leveraging artificial intelligence — are transformative for patient care and address large, unmet medical needs. The firm believes the coming decade will bring a golden age of life sciences innovation driven by AI, and it deploys 'precision capital' supported by a proprietary national medical network platform to nurture companies solving the biggest and most complex medical problems.
Source: firm website, verified Sep 29, 2026.
Team · 21 people
from the firm's website & public directories
Founder mafia
3 people who came through Medical Excellence Capital went on to found or lead other companies.
What they invest in
from 15 of 21 portfolio companiesBiotech ×15Medical Devices ×7Deep Tech ×6Healthtech ×5Digital Health ×4AI & Machine Learning ×2Hardware ×1
HQs:United States×12
Investments · 21 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 32022 · 22021 · 17 dated
ProJenX is a clinical-stage biotechnology company developing novel, brain-penetrant therapies for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS).
BiotechDeep TechMedical DevicesNissequogue, US
Valerie Estess(Director)
BoardJohn Prufeta(Director)inJoni Mancini(Executive Officer)inBrent R. Stockwell(Chair of the Department of Biological Science, Professor at Columbia University)Hynek Wichterle(Jerry and Emily Spiegel Professor at Columbia University)
Board seatEric Heil· per SEC Form D
Ladder Bio (formerly ThirdLaw Molecular) develops Spiroligomer molecules, a class of synthetic, modular fused-ring compounds designed for highly selective binding to target proteins, along with computational design tools for targeted drug discovery.
BiotechDeep TechMedical DevicesBlue Bell, US
Christian Schafmeister(Founder)inEric Heil(Chief Executive Officer)in
Co-investorsHatch BioFundSmartGateVC
Pleno develops a genomic testing instrument platform designed to make multiomics testing faster, lower-cost, and higher-plex than existing methods like NGS, PCR, and microarrays.
BiotechHardwareHealthtech
Co-investorsForesite CapitalDeerfield Management Company
Ladder Bio (formerly ThirdLaw Molecular) develops Spiroligomer molecules, a class of synthetic, modular fused-ring compounds designed for highly selective binding to target proteins.
BiotechDeep TechMedical DevicesBlue Bell, US
Christian Schafmeister(Founder)Eric Heil(Chief Executive Officer)in
Co-investorsSmartGateVC
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)inDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)
Co-investorsARCH Venture PartnersLifeforce CapitalOrbiMedDomain AssociatesEDB InvestmentsSection 32+8 more
Avilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process.
BiotechWaltham, US
THERESA CAMERON(Director)MARTIN FREED(Director)inSTEPHANIE TOZZO(Executive Officer)PHIL GRAHAM(Executive Officer)MILIND DESHPANDE(Director)DAVID NEAFUS(Executive Officer)
Co-investorsAstellas Venture Management LLCRA CapitalSanofi VenturesOpenSky Ventures
ClicBio develops oral small-molecule CLIC1 inhibitors to treat metabolic diseases by modulating appetite through hypothalamic neuron regulation.
BiotechDeep TechHealthtech
John Dobak(CEO and Co-Founder)Jay Hagan(Board Member and Co-Founder)Bruce Steel(Board Member and Co-Founder)Olivia Osborn(Co-Founder/Advisor)
GCTx develops an induced pluripotent stem cell (iPSC) programming platform called TFome™ that uses synthetic biology, gene editing, and machine learning to improve cell therapy development and scaling.
AI & Machine LearningBiotechMedical DevicesCambridge, US
George Church(Co-Founder & Scientific Advisor)Parastoo Khoshakhlagh(Chief Executive Officer & Co-Founder)inAlex Ng(Chief Innovation Officer & Co-Founder)in
Co-investorsAlumni VenturesAndreessen HorowitzGlobal BrainHumboldt
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Amanda Wagner(Executive Officer)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
BoardLaura Brass(Director)inKai Wucherpfennig(Director)
Co-investorsAgent CapitalDC Investment PartnersLongwood FundNovartis Venture FundOno Venture Investment, Inc.Solasta Ventures+3 more
Nobias Therapeutics is a clinical-stage drug developer creating small-molecule therapeutics for genetically-defined rare diseases, initially focused on pediatric indications with potential expansion into adult and non-rare conditions.
AI & Machine LearningBiotechHealthtech
Hakon Hakonarson(Co-Founder and Chief Scientific Advisor)Brian Halak(Co-Founder)inPatrick Dougherty(Chief Executive Officer)Ryan McMillian(Consulting Chief Financial Officer)
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.
BiotechDeep TechDigital HealthHealthtechSouth San Francisco, US
Kenneth Greenberg(Co-Founder, President & CEO)in
Co-investorsVida VenturesLeaps by BayerARCH Venture PartnersFoothill VenturesIllumina VenturesVivo Capital+8 more
San Diego biotech founded in 2019 developing oral anti-inflammatory small molecules targeting RNA binding proteins.
Co-investorsARCH Venture PartnersLightstone VenturesCanaan Partners
Truvian builds an on-site blood diagnostics platform that combines clinical chemistry, immunoassay, and hematology testing in a single compact instrument.
BiotechDigital HealthMedical DevicesSan Diego, US
Dena Marrinucci(Co-Founder & Chief Operating Officer)inMichael J. Mina(Chief Medical and Strategy Officer)in
Co-investorsDns CapitalGreatPoint VenturesWittington VenturesDomain AssociatesEmbark VenturesXB Ventures+1 more
TwoStep Therapeutics is a Stanford spinout developing targeted cancer therapies, including peptide-based drug conjugates and radioligand programs built on a tumor-targeting peptide platform.
BiotechHealthtechSan Carlos, US
Caitlyn Miller(CEO & Co-Founder)inJennifer Cochran(Co-Founder)Carolyn Bertozzi(Co-Founder)Ronald Levy(Co-Founder)
BoardOmri Amirav-Drory(Director)inJohn Prufeta(Director)in
Co-investors2048 VenturesFifty YearsNFX
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rejuvitas, Inc.ClicBioImmunitasLadder BioLadder Bio (formerly ThirdLaw Molecular)Nobias TherapeuticsThirdLaw Molecular
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Portfolio news
latest coverage across their companiesSonoThera · finsmes.com · Jun 10, 2026
Aspen Neuroscience · prnewswire.com · Nov 20, 2025
Frequently asked questions
- How many investments has Medical Excellence Capital made?
- Medical Excellence Capital has 21 tracked investments, including 4 dated in the last 24 months.
- What stage does Medical Excellence Capital invest at?
- Medical Excellence Capital invests at the Pre-Seed, Seed, Series A, Series B stages.
- What sectors does Medical Excellence Capital focus on?
- Medical Excellence Capital focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Medical Excellence Capital located?
- Medical Excellence Capital is headquartered in New York, US.
- Does Medical Excellence Capital lead rounds?
- Medical Excellence Capital typically participates in rounds rather than leading them.
- Who does Medical Excellence Capital co-invest with?
- Medical Excellence Capital most often shares deals with ARCH Venture Partners, Andreessen Horowitz, Global Brain, among 33 tracked co-investors.
From the blog
visit blog ↗Recent posts cover advancements in regenerative medicine including iPSC-derived cell therapies for neurodegenerative diseases and nonviral gene delivery platforms for genetic disorders. AI summary
Media · Podcasts & interviews
featuring the teamAsk an Investor featuring Kim Kamdar of Medical Excellence Capital
UC San Diego Innovation · Kim Kamdar
Co-investors · 16
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
Illuminate Ventures is a seed-stage venture capital firm focused on B2B/enterprise software companies, typically serving as a startup's first institutional investor. It leverages data and AI-driven platforms and applications to help early-stage teams become market leaders.
Foothill Ventures is a technology-focused venture fund based in Los Altos, California, run by a team with founder and operator backgrounds. It makes early-stage investments in frontier technology, particularly infrastructure and AI applications.
Johnson & Johnson Innovation is the innovation arm of Johnson & Johnson, working to advance life science innovation through early partnerships, incubation via JLABS, venture investing through JJDC, and late-stage partnerships to address global health challenges.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
Vida Ventures is a life sciences venture capital firm focused on transforming biomedical innovations into therapies that improve patients' lives.
Agent Capital is a healthcare venture capital firm that makes direct equity investments in novel, differentiated therapeutics and treatments addressing unmet patient needs, from preclinical through commercial stages.
Vertex Ventures HC (VVHC) is a healthcare-focused venture capital fund and part of Vertex's global network of affiliated funds. It backs companies developing transformative therapies and medical technologies, supporting them through key growth and value-creation milestones.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
▶4 more co-investors
MorgenthalerCofounders CapitalQuesta CapitalHealthQuest Capital
Firms observed investing alongside Medical Excellence Capital, from public investor directories. Shared companies are the overlap with Medical Excellence Capital's recorded portfolio.
Similar investors
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Rising Tide is a venture capital firm investing across sectors including healthcare, life sciences, AI infrastructure, space and communications, fintech, and crypto.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.